動物雙歧桿菌乳酸亞種 BB-12 Bifidobacterium animalis subsp. lactis BB-12 × 嬰兒腸絞痛
結論：證據支持但有警示
BB-12 對嬰兒腸絞痛具有 strain-exact 證據支持：L2 確認至少 2 篇雙盲安慰劑對照 RCT（PMID 34550055 與 31797399, n=192, 1×10⁹ CFU/天, 3 週）明確使用 BB-12 菌株顯示能減少哭鬧/煩躁時間，且 NASPGHAN/ESPGHAN 立場文件（L5e）以「may recommend」弱建議形式收錄 BB-12（≥10⁸ CFU/日, 21–28 天）用於母乳哺育嬰兒腸絞痛——此為菌株層級的官方臨床指引引用，極為罕見。
B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
BB-12 對嬰兒腸絞痛具有 strain-exact 證據支持：L2 確認至少 2 篇雙盲安慰劑對照 RCT（PMID 34550055 與 31797399, n=192, 1×10⁹ CFU/天, 3 週）明確使用 BB-12 菌株顯示能減少哭鬧/煩躁時間，且 NASPGHAN/ESPGHAN 立場文件（L5e）以「may recommend」弱建議形式收錄 BB-12（≥10⁸ CFU/日, 21–28 天）用於母乳哺育嬰兒腸絞痛——此為菌株層級的官方臨床指引引用，極為罕見。
然而證據力未達 A 等級的理由：(1) 尚無 BB-12 單一菌株獨立 meta-analysis，2024 年泛菌株 meta（PMID 37962097）未獨立量化 BB-12 效果；(2) 一線首選仍為 L. reuteri DSM 17938（證據最強，平均減少哭鬧 64.66 分鐘/天）；(3) Mayo Clinic（L5b）對嬰兒益生菌整體採保留立場，Cleveland Clinic（L5c）與 Harvard Health（L5d）未對 BB-12 × colic 提供任何 strain-specific 內容；(4) 證據範圍限縮於足月母乳嬰兒，配方奶/剖腹產嬰兒證據不足。
整體屬「strain-exact 中度證據」，符合 B 等級。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.67
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
73%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.667
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic - a randomised, double-blinded, placebo-controlled study
— 詳細結論請見 PubMed 原文
前往 PubMed
The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial
— 詳細結論請見 PubMed 原文
前往 PubMed
Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review
— 詳細結論請見 PubMed 原文
前往 PubMed
L4a US FDA
支持
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). 來源↗
L4b EU EFSA
謹慎
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… 來源↗
L4c UK NHS
謹慎
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… 來源↗
L4d TW TFDA / 衛福部
中性
— 本適應症無對應資料
L4e WHO
中性
— 本適應症無對應資料
L5a NIH Office of Dietary Supplements
支持
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … 來源↗
L5b Mayo Clinic
謹慎
One factor that may add to colic is that the good bacteria in an infant's gut is out of balance, and one treatment being studied is the use of good bacteria, called probiotics. Probiotics might help the bacterial balance to improve overall gut health. Some studies have shown less crying time when babies with colic were treated with a bacterium called Lactobacillus reuteri. However, the studies … 來源↗
L5c Cleveland Clinic
中性
— 本適應症無對應資料
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
支持
Healthcare providers may recommend B lactis BB-12 (at least 10^8 CFU/day, for 21-28 days) for the management of infant colic in breastfed infants. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣媽媽社群討論嬰兒腸絞痛時，主流推薦壓倒性集中在羅伊氏乳酸桿菌 L. reuteri DSM 17938（寶乖亞/BioGaia），而非 BB-12；BB-12 在 TW 市場多以「LGG+BB-12」複方型式出現（如妙可適滴劑），定位偏向幫助排便、調整體質與一般腸道保健，並非專門針對腸絞痛的菌株。社群對「BB-12 × 腸絞痛」的直接經驗分享非常稀少，多為泛指「益生菌」的討論。
💬社群實感
資料不足
破解迷思 社群最常見的 4 個誤解
✓
事實誤把 BB-12 與 L. reuteri DSM 17938 視為相同功效，實際上腸絞痛主流研究菌株是後者
✓
事實認為所有比菲德氏菌（雙歧桿菌）都對腸絞痛有效，忽略菌株差異
✓
事實以為買 LGG+BB-12 複方就能治腸絞痛，但複方研究多為一般腸道保健而非 colic
✓
事實把 BB-12 與優酪乳發酵菌（同屬 B. lactis 但非 BB-12 株）混為一談
🩹 社群通報的副作用
- 少數媽媽提到加益生菌後寶寶喝奶變抗拒（味道問題，多為複方反應而非單一 BB-12）
- 極少數反映排便頻率改變（變少或變稀），多在 2-3 天內適應
- BB-12 本身在 TW 社群未見明確副作用報告
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 妙可適（LGG+BB-12 滴劑）
- 寶乖亞 BioGaia（L. reuteri DSM 17938，腸絞痛主流推薦）
- 新兒寶 Plus+
- 齒妍堂寶貝盾
- Culturelle 康萃樂
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 餵食姿勢與安撫策略 (5S)
- L. reuteri DSM 17938 (母乳寶寶)
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-infant-colic-INT-bifidobacterium-animalis-bb-12-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "動物雙歧桿菌乳酸亞種 BB-12能改善嬰兒腸絞痛",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}